Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in EnglandPharmacoEconomics - Open - Tập 3 - Trang 43-54 - 2018
D. Lee, A. Amadi, J. Sabater, J. Ellis, H. Johnson, S. Kotapati, S. McNamara, A. Walker, M. Cooper, K. Patterson, N. Roskell, Y. Meng
Economic Evaluation of Using Daily Prednisolone versus Placebo at the Time of an Upper Respiratory Tract Infection for the Management of Children with Steroid-Sensitive Nephrotic Syndrome: A Model-Based AnalysisPharmacoEconomics - Open - Tập 6 - Trang 605-617 - 2022
Nafsika Afentou, Emma Frew, Samir Mehta, Natalie J. Ives, Rebecca L. Woolley, Elizabeth A. Brettell, Adam R. Khan, David V. Milford, Detlef Bockenhauer, Moin A. Saleem, Angela S. Hall, Ania Koziell, Heather Maxwell, Shivaram Hegde, Eric Finlay, Rodney D. Gilbert, Caroline Jones, Karl McKeever, Wendy Cook, Nicholas J. A. Webb, Martin T. Christian